Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mint nicotine gum approved

This article was originally published in The Tan Sheet

Executive Summary

FDA approves Dec. 29 Corona, Calif.-based Watson Laboratories' mint-flavored OTC Nicotine Polacrilex gum in 2 mg and 4 mg. The gum is the generic equivalent of GlaxoSmithKline Consumer Healthcare's Nicorette fresh mint gum, and will hit store shelves in early January. More than $300 million of nicotine gum was sold in the 12 months ending September 2008, according to Information Resources Inc. sales data

You may also be interested in...

FDA okays Watson's flavored nicotine gum

FDA approves Morristown, N.J.-based Watson Laboratories' sale of 2 mg and 4 mg nicotine polacrilex gum coated with fruit and cinnamon flavors. The name brand equivalent Nicorette Fruit Chill and Cinnamon Sugar Coated Gums helped GlaxoSmithKline sell more than $305 million of the gum in the 12 months ending March 29, Watson says in a July 8 release. FDA approved Watson's mint-flavored equivalent of GlaxoSmithKline Consumer Healthcare's Nicorette gum in December 2008 (1"The Tan Sheet" Jan. 5, 2009, In Brief)

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts